Inari Medical (NARI)
(Delayed Data from NSDQ)
$38.42 USD
+0.35 (0.92%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $38.40 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Company Summary
Irvine CA-based Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. The company’s initial product offering comprises two minimally-invasive, novel catheter-based mechanical thrombectomy devices. Inari Medical built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism, or VTE (deep vein thrombosis and pulmonary embolism). The company’s FDA-cleared ClotTriever product helps in the removal of clot from peripheral blood vessels and ...
Company Summary
Irvine CA-based Inari Medical, Inc. is a commercial-stage medical device company committed toward developing products to treat and change the lives of patients suffering from venous diseases. The company’s initial product offering comprises two minimally-invasive, novel catheter-based mechanical thrombectomy devices. Inari Medical built its products purposely on the basis of the specific characteristics of the venous system and the treatment of the two distinct indications of venous thromboembolism, or VTE (deep vein thrombosis and pulmonary embolism). The company’s FDA-cleared ClotTriever product helps in the removal of clot from peripheral blood vessels and to treat patients suffering from deep vein thrombosis (DVT). Meanwhile, its FlowTriever product is the first thrombectomy system, which is FDA-cleared, used for the treatment of pulmonary embolism (PE). Both the products have been created to do away with the need for thrombolytic drugs.
In fact, these products have been utilized to treat more than 20,000 patients at above 800 hospitals throughout the United States. Inari Medical witnessed substantial growth since it started to commercialize its products, with around 13,200 procedures performed utilizing its products in 2020. The company is focused on building a solid base of clinical evidence and real-world patient outcomes to further support the safety and effectiveness of its products.
The company’s key relationships are between its sales representatives and treating physicians, including interventional cardiologists, radiologists and vascular surgeons. Inari Medical has built systems and processes to control the information stemming from these relationships, thereby helping it to quickly iterate products, launch and execute physician education and training programs and scale its sales organization. The company markets and sells its products to hospitals that are reimbursed by numerous third-party payors.
2023 at a Glance
In 2023, adjusted loss per share came in at 3 cents, compared with 55 cents in the previous year. Full-year 20232 revenue was $493.6 million, up 28.7% from the previous year.
General Information
Inari Medical, Inc
6001 Oak Canyon Suite 100
Irvine, CA 92618
Phone: 877-923-4747
Fax: NA
Web: http://www.inarimedical.com
Email: ir@inarimedical.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 4/30/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.11 |
Current Year EPS Consensus Estimate | -0.25 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 4/30/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 38.07 |
52 Week High | 71.85 |
52 Week Low | 36.73 |
Beta | 0.84 |
20 Day Moving Average | 981,529.00 |
Target Price Consensus | 73.70 |
4 Week | -20.65 |
12 Week | -34.04 |
YTD | -41.36 |
4 Week | -17.42 |
12 Week | -35.90 |
YTD | -44.60 |
Shares Outstanding (millions) | 57.96 |
Market Capitalization (millions) | 2,206.56 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | 380.70 |
PEG Ratio | NA |
vs. Previous Year | 145.45% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 22.57% |
vs. Previous Quarter | 4.53% |
Price/Book | 4.72 |
Price/Cash Flow | 431.76 |
Price / Sales | 4.47 |
3/31/24 | NA |
12/31/23 | 1.23 |
9/30/23 | -0.64 |
3/31/24 | NA |
12/31/23 | 0.97 |
9/30/23 | -0.53 |
3/31/24 | NA |
12/31/23 | 3.09 |
9/30/23 | 7.10 |
3/31/24 | NA |
12/31/23 | 2.52 |
9/30/23 | 6.49 |
3/31/24 | NA |
12/31/23 | 1.11 |
9/30/23 | -0.59 |
3/31/24 | NA |
12/31/23 | -0.33 |
9/30/23 | -0.59 |
3/31/24 | NA |
12/31/23 | 0.86 |
9/30/23 | 0.56 |
3/31/24 | NA |
12/31/23 | 8.07 |
9/30/23 | 7.85 |
3/31/24 | NA |
12/31/23 | 1.49 |
9/30/23 | 1.49 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |